No abstract available.
Fluorodeoxyglucose F18 ; Neurilemmoma ; Spine

No abstract available.
Colon ; Fluorodeoxyglucose F18

No abstract available.
Colon ; Fluorodeoxyglucose F18 ; Ulcer

Breast lymphomas, either manifesting as a primary extranodal disease or secondary involvement, are a rare form of malignancy. Breast lymphomas can be visualized as hypermetabolic lesions in 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) scans. Here, we describe a case of a secondary breast lymphoma, detected with 18F-FDG PET/CT.
Breast ; Fluorodeoxyglucose F18 ; Lymphoma

No abstract available.
Diagnosis, Differential* ; Fluorodeoxyglucose F18* ; Polyps*

No abstract available.
Fluorodeoxyglucose F18 ; Humans ; Lymphoid Tissue ; Lymphoma

No abstract available.
Fluorodeoxyglucose F18* ; Thyroid Gland* ; Thyroid Neoplasms*

PURPOSE: To compare characteristic findings of 18F-FDG PET/CT with ultrasonography of malignant thyroid incidentaloma. MATERIALS AND METHODS: This study enrolled 74 patients receiving ultrasonography after thyroid incidentaloma detected on 18F-FDG PET/CT. We analyzed the size, attenuation, margin, cervical lymphadenopathy, and P-SUV of thyroid incidentaloma in 18F-FDG PET/CT and analyzed the size, internal contents, appearance, border, echo, and calcification patterns of thyroid incidentaloma in ultrasonography. Based on pathologic findings, we investigated findings of 18F-FDG PET/CT and ultrasonography for malignant thyroid incidentaloma. RESULTS: In 18F-FDG PET/CT findings, an ill-defined margin accompanied by cervical lymphadenopathy was more common in malignant (59.1%) than benign (13.2%) lesions (p < 0.05). There were no significant differences in p-SUV between malignant and benign thyroid incidentalomas (4.8+/-18.3 vs. 4.4+/-2.2). In ultrasonographic findings, being taller than wide (1.9% vs. 36.4%), having a well-defined speculated margin (75.5% vs. 22.7%), having marked hypoechoic images (18.9% vs. 31.8%), and having micro (5.7% vs. 22.7%) or macrocalcifications (3.8% vs. 27.3%) were more common in malignant thyroid incidentalomas (p < 0.05). CONCLUSION: Malignant thyroid incidentalomas in 18F-FDG PET/CT have ill-defined margins, and those in ultrasonography were the taller than wide, well defined spiculated margin, and showed micro or macrocalcification.
Fluorodeoxyglucose F18 ; Humans ; Lymphatic Diseases ; Thyroid Gland

Background: Breast cancer is the second most common malignancy globally. This study is a systematic review and meta-analysis assessing whole-body PET/CT using 18F-FDG in detecting breast carcinoma distant metastases as an update to the study of Xu et al. Objective: To determine the diagnostic accuracy of whole-body PET/CT in distant metastasis detection among breast cancer patients. Methods: The MEDLINE database was systematically searched for articles evaluating whole-body PET/CT in distant metastasis detection among breast cancer patients. Sensitivity, specificity, likelihood ratios and predictive values were derived by the three independent readers. Summary receiver operating characteristic curves were plotted. Results: Fifteen studies (n=4175) were included with pooled sensitivities, specificities, positive and negative likelihood ratios, positive and negative predictive values (with 95% confidence intervals) of 0.98 (0.97-0.99), 0.98 (0.98-0.99), 86.6 (63.6-117.9), 0.01 (0.01-0.02), 0.94 (0.92-0.95) and 0.99 (0.995-0-.998), respectively. Pooled positive and negative predictive values with a prevalence of 13.6% are 0. 93 and 0.99, respectively. Conclusion Whole-body PET/CT with 18F-FDG provides excellent detection of distant metastases in breast cancer and is recommended in assessing patients in earlier stages of the disease, not only in the later stages, especially in more aggressive tumors.
Fluorodeoxyglucose F18 ; Carcinoma ; Meta-analysis ; Breast Neoplasms

Primary malignant melanoma of the esophagus (PMME) is an exceptionally rare condition, representing a mere 0.1 to 0.2% of esophageal cancers, and accounting for just 0.1 to 0.5% of all melanomas. This case involves a 39 -year-old Filipino male who sought medical attention after an episode of choking. Subsequently, endoscopy with biopsy revealed a mass in the distal third of the esophagus, ultimately diagnosed as PMME based on histopathology and immunohistochemistry. FDG-PET/CT scan revealed a hypermetabolic distal esophageal mass and a confluent upper paratracheal lymphadenopathy. He was initially treated with Pembrolizumab, Nivolumab, and Ipilimumab immunotherapy. However, post-treatment FDG PET/CT scans unveiled metabolic progression of the esophageal mass with new hypermetabolic cervical lymph nodes, necessitating a shift to carboplatin and paclitaxel chemotherapy. After two cycles, there was a notable metabolic regression of the mass and paratracheal node with metabolic resolution of the cervical lymph node. An additional 2 cycles of chemotherapy were given, aimed to further reduce the size of the tumor, however, a succeeding follow-up study revealed metabolic progression of the mass. Surgical resection of both the esophageal mass and paratracheal nodes became imperative. The aggressive characteristics, metastasis at early diagnosis, and lack of effective treatment have contributed to the poor prognosis of PMME. Total esophagectomy is the preferred method of treatment. Chemotherapy and immunotherapy may be used in advanced diseases but with variable efficacy. The utilization of FDG PET/CT scans plays a crucial role in both the initial staging and the ongoing assessment of treatment response in patients diagnosed with PMME. This advanced imaging modality offers valuable insights into the extent of the disease and aids clinicians in evaluating the effectiveness of the chosen therapeutic interventions. Given the rarity and challenges associated with PMME, a multidisciplinary approach integrating surgical, medical, and imaging strategies is essential for comprehensive patient care.
Melanoma ; Positron-Emission Tomography ; Fluorodeoxyglucose F18 ; Immunotherapy